All In Biotech

Drug Trial Radar · NCT00487539

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Feb 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,065 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,065

Actual

Start

Aug 2007

Primary completion

Oct 2010

Study completion Oct 2010

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jun 18, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with ulcerative colitis (UC).

Conditions

  • Colitis, Ulcerative

Interventions

  • PlaceboBiological

    Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.

  • Golimumab 100 mgBiological

    Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -\> 50 mg arm group and at Week 2 for Golimumab 200 mg -\> 100 mg arm group.

  • Golimumab 200 mgBiological

    Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -\> 100 mg arm group and at Week 2 for Golimumab 400 mg -\> 200 mg arm group.

  • Golimumab 400 mgBiological

    Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -\> 200 mg arm group.

  • Golimumab 50 mgBiological

    Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -\> 50 mg arm group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinical Response at Week 6Time frame: Baseline, Week 6

Locations

200 sites in 25 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Roseville, California

  • Site not named

    San Diego, California

  • Site not named

    Golden, Colorado

  • Site not named

    Newark, Delaware

  • Site not named

    Boca Raton, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Naples, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Port Orange, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Zephyrhills, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Arlington Heights, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Clive, Iowa

  • Site not named

    Pratt, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    Monroe, Louisiana

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Troy, Michigan

  • Site not named

    Rochester, Minnesota

  • Site not named

    Pascagoula, Mississippi

  • Site not named

    Tupelo, Mississippi

  • Site not named

    Egg Harbor, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Rochester, New York

  • Site not named

    Asheville, North Carolina

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Morganton, North Carolina

  • Site not named

    New Bern, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Wilmington, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Fargo, North Dakota

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

Showing 40 of 200 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.